Invitae Tuberous Sclerosis Complex Panel


Test description

This test analyzes the TSC1 and TSC2 genes. Pathogenic variants in these genes are associated with tuberous sclerosis complex (TSC). Characteristics of TSC include benign tumors in the brain, kidneys, lungs, heart, and skin, as well as seizures, intellectual disability, and increased risk of brain and kidney cancer.

Many of the features of TSC are nonspecific, can occur as isolated findings, and can present as features of other conditions. Genetic testing may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.

Order test

Primary panel (2 genes)


Alternative tests to consider

TSC1 and TSC2 can also be ordered as part of a broader panel to test for different types of hereditary cancer conditions. Depending on the individual’s clinical and family history, one of these broader panels may be appropriate. Any of these broader panels can be ordered for no additional charge.

  • Tuberous sclerosis complex (TSC)
    • Tuberous sclerosis complex type 1 (TSC1)
    • Tuberous sclerosis complex type 2 (TSC2)

Tuberous sclerosis complex (TSC) is a highly variable condition whose features include numerous benign tumors of the skin, brain, kidneys, lungs, heart, and other organs. TSC can also cause mild-to-severe neurodevelopmental and behavioral impairments, often manifesting as autism spectrum disorder.

Most affected individuals develop non-malignant brain tumors that have malignant potential, specifically cortical tubers, subependymal nodules, and subependymal giant cell astrocytomas; these are easily identified by neuroimaging. These lesions are often associated with seizures; TSC is a known cause of infantile spasm/hypsarrhythmia syndrome.

Renal tumors develop in most cases. While typically non-malignant, these tumors can lead to life-threatening renal disease. Such lesions include benign angiomyolipoma, epithelial cysts, and oncocytoma. Though uncommon, renal cancers associated with TSC include malignant angiomyolipoma and renal cell carcinoma.

Benign cardiac and pulmonary tumors are also features of TSC. Adult-onset lymphangiomyomatosis develop primarily in women. Cardiac rhabdomyomas, if present, are often seen on prenatal ultrasound and are largest in the neonatal period. These tumors regress and ultimately disappear; fortunately, surgical intervention is unnecessary in most cases.

Virtually everyone with TSC has one or more of the characteristic skin findings, which include hypopigmented (hypomelanotic) macules, shagreen patches, facial angiofibromas, fibrous facial plaques, and ungual fibromas.

Essentially all individuals with a disease-causing pathogenic variant in TSC1 or TSC2 will express the condition and manifest symptoms, often beginning in childhood. TSC is highly variable, though, and the signs and symptoms can vary significantly among affected individuals, even among family members. Because we cannot predict which cancers may develop, additional medical management strategies focused on cancer prevention and early detection may benefit most patients who are found to have a pathogenic variant.

Cancer typeLifetime risk
Brain (subependymal giant cell astrocytomas)6%-14%
Kidney (malignant angiomyolipoma, renal cell carcinoma)2%-5%

Pathogenic variants in TSC1 and TSC2 are identified in approximately 85% of individuals who meet the clinical diagnostic criteria for TSC.

Approximately one third of cases are inherited from an affected parent in an autosomal dominant pattern. The remainder are sporadic and occur as the result of a spontaneous de novo mutation.

The prevalence of TSC is approximately 1 in 6,000 individuals.

Analysis of the TSC1 and TSC2 genes may be considered in individuals with features including:

  • facial angiofibromas or forehead plaque
  • periungual fibromas
  • hypomelanotic macules
  • shagreen patch
  • iris hamartomas
  • cortical tubers
  • subependymal nodules
  • subependymal giant cell astrocytoma
  • cardiac rhabdomyoma
  • lymphangiomyomatosis
  • renal angiomyolipoma

Clinical diagnostic criteria for tuberous sclerosis have also been proposed:

Assay and technical information

Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).

Our sequence analysis covers clinically important regions of each gene, including coding exons, +/- 10 base pairs of adjacent intronic sequence, and select noncoding variants. Our assay provides a Q30 quality-adjusted mean coverage depth of 350x (50x minimum, or supplemented with additional analysis). Variants classified as pathogenic or likely pathogenic are confirmed with orthogonal methods, except individual variants that have high quality scores and previously validated in at least ten unrelated samples.

Our analysis detects most intragenic deletions and duplications at single exon resolution. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. If you are requesting the detection of a specific single-exon copy number variation, please contact Client Services before placing your order.

Gene Transcript reference Sequencing analysis Deletion/Duplication analysis
TSC1 NM_000368.4
TSC2 NM_000548.3